/

Società

LA

Società

LAMINAR PHARMA

Di cosa scriviamo

IndustriaMetallurgiaOncologiaSaluteSanità

11 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

11/03/2025

Salute

Sanità

Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients - laminarpharma

Fonte

1.00

0

Press Release cover image

17/06/2024

Salute

Oncologia

Sanità

Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma. - laminarpharma

Fonte

1.00

0

Press Release cover image

06/03/2024

Salute

Oncologia

Sanità

Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma. - laminarpharma

Fonte

1.00

0

Press Release cover image

11/09/2023

Salute

Sanità

Laminar Pharma Receives Rare Pediatric Disease Designation from the U.S. FDA for LAM561 - laminarpharma

Fonte

1.00

0

Press Release cover image

10/08/2022

Salute

Oncologia

Sanità

Hope versus experience in glioblastoma - laminarpharma

Fonte

1.00

0

Press Release cover image

13/07/2021

Musica

Salute

Sanità

Investment in Spanish biotech is at an all-time high - laminarpharma

Fonte

1.00

0

24/06/2021

Industria

Metallurgia

Meccanica

Zoologia

Ecologia/Salute ambientale

Valencia Plaza - laminarpharma

Fonte

1.00

0

21/06/2021

Industria

Metallurgia

Meccanica

Zoologia

Ecologia/Salute ambientale

Alicante Plaza - laminarpharma

Fonte

1.00

0

Press Release cover image

05/05/2021

Musica

Salute

Sanità

Laminar partners with charity Sonrisa Médica to bring joy to hospitalised children - laminarpharma

Fonte

1.00

0

Press Release cover image

23/03/2021

Salute

Oncologia

Sanità

Meet the CEO: Dr. Pablo Escribá - laminarpharma

Fonte

1.00

0

Seguaci

0

Compatibilità

0